Therapeutic Area: Oncology
Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
Whangbo et al.
Blood Advances
April 2019
Authors and Affiliates
Whangbo JS1,2,3,4, Kim HT5,6, Nikiforow S3,4, Koreth J3,4, Alho AC3,4,7, Falahee B3,4, Kim S3,4, Dusenbury K3,4, Fields MJ3,4, Reynolds CG3,4, Alyea EP 3rd3,4, Armand P3,4, Cutler CS3,4, Ho VT3,4, Antin JH3,4, Soiffer RJ3,4, Ritz J3,4
1
Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
2
Department of Pediatric Oncology and.
3
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
4
Harvard Medical School, Boston, MA.
5
Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
6
Harvard School of Public Health, Boston, MA; and.
7
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Mobilization of CD8þ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
Authors and Affiliates
Seo YD1, Jiang X#1, Sullivan KM#1, Jalikis FG2, Smythe KS3, Abbasi A1, Vignali M4, Park JO1, Daniel SK1, Pollack SM3, Kim TS1, Yeung R1, Crispe IN2, Pierce RH3, Robins H3,4, Pillarisetty VG5; 1Department of Surgery, University of Washington, Seattle, Washington.
2
Department of Pathology, University of Washington, Seattle, Washington.
3
Fred Hutchinson Cancer Research Center, Seattle, Washington.
4
Adaptive Biotechnologies, Seattle, Washington.
5
Department of Surgery, University of Washington, Seattle, Washington. vgp@uw.edu.
#
Contributed equally
The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma
Agdashian et al.
Cancer Immunology and Immunotherapy
April 2019
Authors and Affiliates
Agdashian D1, ElGindi M1, Xie C1, Sandhu M1, Pratt D2, Kleiner DE2, Figg WD3, Rytlewski JA4, Sanders C4, Yusko EC4, Wood B5, Venzon D6, Brar G1, Duffy AG1, Greten TF7,8, Korangy F1.
1
Gastrointestinal Malignancies Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Building 10, Room 3B43, Bethesda, MD, 20892, USA.
2
Laboratory of Pathology, Center for Cancer Research (CCR) National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
3
Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
4
Adaptive Biotechnologies, Seattle, WA, USA.
5
Center for Interventional Oncology, Radiology and Imaging Sciences and Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
6
Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
7
Gastrointestinal Malignancies Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Building 10, Room 3B43, Bethesda, MD, 20892, USA. tim.greten@nih.gov.
8
NCI CCR Liver Cancer Program, Bethesda, MD, USA.
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Sawant et al.
Nature Immunology
April 2019
Authors and Affiliates
Sawant DV1,2, Yano H1,3, Chikina M4, Zhang Q1,5, Liao M1,6, Liu C1, Callahan DJ1,3, Sun Z7, Sun T7, Tabib T8, Pennathur A9, Corry DB10, Luketich JD9, Lafyatis R8, Chen W7, Poholek AC1,11, Bruno TC1,12,13, Workman CJ1, Vignali DAA14,15,16; 1
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
2
Department of Inflammation and Oncology, Discovery Research, Amgen, South San Francisco, CA, USA.
3
Program in Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
4
Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
5
Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
6
The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
7
Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA.
8
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
9
Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
10
Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
11
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
12
Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
13
Cancer Immunology & Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
14
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. dvignali@pitt.edu.
15
Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. dvignali@pitt.edu.
16
Cancer Immunology & Immunotherapy Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. dvignali@pitt.edu.
Subclonal STAT3 mutations solidify clonal dominance
Authors and Affiliates
Cassandra M. Kerr,1 Michael J. Clemente,1 Peter W. Chomczynski,1 Bartlomiej Przychodzen,1 Yasunobu Nagata,1 Vera Adema,1 Valeria Visconte,1 Alan E. Lichtin,2 Satu Mustjoki,3,4 Tomas Radivoyevitch,5 Mikkael A. Sekeres,2 and Jaroslaw P. Maciejewski1,2
1Department of Translational Hematology and Oncology Research and
2Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;
3Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland;
4Department of Hematology, Helsinki University Hospital Comprehensive Cancer Centre, Helsinki, Finland; and
5Quantitative Health Sciences Department, Cleveland Clinic, Cleveland, OH
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Cloughesy et al.
Nature Medicine
March 2019
Authors and Affiliates
Cloughesy TF1,2,3, Mochizuki AY4, Orpilla JR5, Hugo W6, Lee AH7,5, Davidson TB8,4, Wang AC5, Ellingson BM8,9, Rytlewski JA10, Sanders CM10, Kawaguchi ES11, Du L11, Li G8,11, Yong WH12, Gaffey SC13, Cohen AL14, Mellinghoff IK15, Lee EQ13, Reardon DA13, O'Brien BJ16, Butowski NA17, Nghiemphu PL18, Clarke JL17, Arrillaga-Romany IC19, Colman H14, Kaley TJ15, de Groot JF16, Liau LM8,5, Wen PY13, Prins RM20,21,22,23.
1
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. tcloughesy@mednet.ucla.edu.
2
Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. tcloughesy@mednet.ucla.edu.
3
Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. tcloughesy@mednet.ucla.edu.
4
Division of Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
5
Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
6
Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
7
Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
8
Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
9
Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
10
Adaptive Biotechnologies, Seattle, WA, USA.
11
Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.
12
Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
13
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
14
Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
15
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
16
Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
17
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
18
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
19
Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
20
Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. rprins@mednet.ucla.edu.
21
Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. rprins@mednet.ucla.edu.
22
Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. rprins@mednet.ucla.edu.
23
Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. rprins@mednet.ucla.edu.
Graft γδ TCR Sequencing Identifies Public Clonotypes Associated with Hematopoietic Stem Cell Transplantation Efficacy in Acute Myeloid Leukemia Patients and Unravels Cytomegalovirus Impact on Repertoire Distribution
Authors and Affiliates
Arruda LCM1, Gaballa A2, Uhlin M2,3,4.
1 Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm 141 86, Sweden; lucas.arruda@ki.se.
2
Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm 141 86, Sweden.
3
Department of Applied Physics, Science for Life Laboratory, Royal Institute of Technology, Stockholm 141 86, Sweden; and.
4
Department of Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm 141 86, Sweden.
Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood.
Authors and Affiliates
Rytlewski J1, Deng S2, Xie T2, Davis C2, Robins H1,3, Yusko E1, Bienkowska J2
1 Adaptive Biotechnologies, Seattle, Washington, United States of America.
2
Pfizer Incorporated, La Jolla, California, United States of America.
3
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells
Montel-Hagen wt al.
Cell Stem Cell
March 2019
Authors and Affiliates
Montel-Hagen A1, Seet CS2, Li S3, Chick B1, Zhu Y1, Chang P4, Tsai S5, Sun V4, Lopez S1, Chen HC1, He C1, Chin CJ1, Casero D1, Crooks GM6
1
Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
2
Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; Broad Stem Cell Research Center, UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA.
3
Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; Broad Stem Cell Research Center, UCLA, Los Angeles, CA, USA; Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA.
4
Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; Molecular Biology Interdepartmental Program, UCLA, Los Angeles, CA, USA.
5
Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
6
Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; Broad Stem Cell Research Center, UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA; Division of Pediatric Hematology-Oncology, Department of Pediatrics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. Electronic address: gcrooks@mednet.ucla.edu